Search Result

Results for "

pik3ca

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (10) Apoptosis (9) Autophagy (2) Bcl-2 Family (2) c-Myc (1) Drug Intermediate (1) Epigenetic Reader Domain (1) GSK-3 (2) MMP (1) mTOR (5) Organoid (2) p38 MAPK (1) PARP (1) PI3K (11) Reactive Oxygen Species (ROS) (1) Reference Standards (4) Ser/Thr Protease (1) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (21) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (5) Metabolic Disease (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10358

MK-2206 dihydrochloride Maximum Cited Publications 462 Publications Verification MK-2206 (2HCl)	Bcl-2 Family Apoptosis mTOR Akt GSK-3	Cardiovascular Disease Inflammation/Immunology Cancer
MK-2206 dihydrochloride (MK-2206 2HCl) is an orally active pan-AKT inhibitor, with IC₅₀ values of 8 nM, 12 nM and 65 nM against AKT1, AKT2 and *AKT3, respectively. MK-2206 dihydrochloride inhibits the Akt/mTOR* signaling pathway and reduces the levels of downstream *GSK3β* and Mcl-1 via proteasomal degradation. MK-2206 dihydrochloride induces G1-phase cell cycle arrest, apoptosis, epithelial-mesenchymal transition, fibroblast activation and extracellular matrix deposition. MK-2206 dihydrochloride causes transient hyperglycemia and hyperinsulinemia in animals. MK-2206 dihydrochloride can be used in research related to solid tumors, renal fibrosis and hypercholesterolemia ^[3] .

HY-15244

Alpelisib 120+ Cited Publications BYL-719	PI3K Apoptosis	Cancer
Alpelisib (BYL-719) is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to *PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch* and JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome ^[3] .

HY-108232

MK-2206 Maximum Cited Publications 462 Publications Verification	Bcl-2 Family Apoptosis mTOR Akt GSK-3	Metabolic Disease Inflammation/Immunology Cancer
MK-2206 is an orally active pan-AKT inhibitor, with IC₅₀ values of 8 nM, 12 nM and 65 nM against AKT1, AKT2 and *AKT3, respectively. MK-2206 inhibits the Akt/mTOR* signaling pathway and reduces the levels of downstream *GSK3β* and Mcl-1 via proteasomal degradation. MK-2206 induces G1-phase cell cycle arrest, apoptosis, epithelial-mesenchymal transition, fibroblast activation and extracellular matrix deposition. MK-2206 causes transient hyperglycemia and hyperinsulinemia in animals. MK-2206 can be used in research related to solid tumors, renal fibrosis and hypercholesterolemia ^[3] .

HY-153306

Zovegalisib 1 Publications Verification RLY-2608	PI3K	Cancer
Zovegalisib (RLY-2608) is an orally active first-in-class allosteric mutant-selective inhibitor of *PI3Ka* with anti-tumor activity. Zovegalisib inhibits tumor growth in PIK3CA-mutant xenograft mice models with minimal impact on insulin ^[3].

HY-13898

Taselisib 20+ Cited Publications GDC-0032; RG-7604	PI3K	Cancer
Taselisib (GDC-0032) is a potent *PI3K* inhibitor targets PIK3CA mutations, with K_is of 0.12 nM, 0.29 nM, 0.97 nM, and 9.1 nM for PI3Kδ, PI3Kα, PI3Kγ and PI3Kβ, respectively.

HY-126077

MTI-31 1 Publications Verification LXI-15029	mTOR	Inflammation/Immunology Cancer
MTI-31 (LXI-15029) is a potent, orally active and highly selective inhibitor of mTORC1 and mTORC2. MTI-31 is selective for mTOR (K_d: 0.20 nM) versus PIK3CA, PIK3CB and PIK3G with >5,000 fold selectivity in mTOR binding assays. MTI-31 shows an IC₅₀ of 39 nM for mTOR in LANCE assay of mTOR substrate phosphorylation with 100 μM ATP. MTI-31 can be used for the research of breast cancer .

HY-137849

RK-582	PARP	Cancer
RK-582 is a tankyrase inhibitor, antitumor agent, and orally bioavailable growth inhibitor, with an IC₅₀ of 36.1 nM against human tankyrase-1 and an IC₅₀ of 39.2 nM against human tankyrase-2. In APC-mutated colorectal cancer cells, the sensitivity to RK-582 correlates with the level of active β-catenin, while drug resistance associates with PIK3CA mutation. RK-582 can be used for the research of colorectal cancer .

HY-137458

Vevorisertib 1 Publications Verification ARQ 751	Akt Ser/Thr Protease	Cancer
Vevorisertib (ARQ 751) is an orally active, potent and selective pan-AKT serine/threonine kinase inhibitor against AKT1 (IC₅₀=0.55 nM), AKT2 (IC₅₀=0.81 nM), and *AKT3* (IC₅₀=1.31 nM). Vevorisertib, as a single agent or in combination with other anti-cancer agents, can be used for the research of solid tumors with PIK3CA / AKT / PTEN mutations ^[3] .

HY-100886

BAY1082439	PI3K Apoptosis	Cancer
BAY1082439 is an orally bioavailable, selective PI3Kα/β/δ inhibitor. BAY1082439 also inhibits mutated forms of PIK3CA. BAY1082439 is highly effective in inhibiting Pten-null prostate cancer growth .

HY-137458A

Vevorisertib trihydrochloride 1 Publications Verification ARQ 751 trihydrochloride	Akt	Cancer
Vevorisertib (ARQ 751) trihydrochloride is a selective, allosteric, pan-AKT and AKT1-E17K mutant inhibitors. Vevorisertib trihydrochloride potently inhibit phosphorylation of AKT. Vevorisertib trihydrochloride has Kd values of 1.2 nM and 8.6 nM for AKT1 and AKT1-E17K, respectively. Vevorisertib trihydrochloride has IC₅₀ values of 0.55, 0.81, and 1.3 nM for AKT1, AKT2, and AKT3, respectively. Vevorisertib trihydrochloride can be used for the research of cancer .

HY-15244R

Alpelisib (Standard) BYL-719 (Standard)	Reference Standards PI3K Apoptosis	Cancer
Alpelisib (Standard) is the analytical standard of Alpelisib. This product is intended for research and analytical applications. Alpelisib (BYL-719) is a potent, selective, and orally active PI3Kα inhibitor. Alpelisib (BYL-719) shows efficacy in targeting PIK3CA-mutated cancer. Alpelisib (BYL-719) also inhibits p110α/p110γ/p110δ/p110β with IC50s of 5/250/290/1200 nM, respectively. Antineoplastic activity ^[3].

HY-RS10523

PIK3CA Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PIK3CA Human Pre-designed siRNA Set A contains three designed siRNAs for PIK3CA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PIK3CA Human Pre-designed siRNA Set A PIK3CA Human Pre-designed siRNA Set A

HY-RS10524

Pik3ca Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Pik3ca Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pik3ca gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pik3ca Mouse Pre-designed siRNA Set A Pik3ca Mouse Pre-designed siRNA Set A

HY-RS10525

Pik3ca Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Pik3ca Rat Pre-designed siRNA Set A contains three designed siRNAs for Pik3ca gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pik3ca Rat Pre-designed siRNA Set A Pik3ca Rat Pre-designed siRNA Set A

HY-N12726

Halociline	p38 MAPK MMP	Infection Inflammation/Immunology Cancer
Halociline, a derivative of alkaloids, that can be isolated from the marine fungus Penicillium griseofulvum. Halociline targets MAPK1, MMP-9, and PIK3CA in gastric cancer cells, potentially mediated by diverse pathways including cancer, lipid metabolism, atherosclerosis, and EGFR tyrosine kinase inhibitor resistance. Halociline possesses antimicrobial, antioxidant and biofilm inhibitory activities .

HY-172964

KIM-161	PI3K Akt mTOR Apoptosis Reactive Oxygen Species (ROS)	Cancer
KIM-161 is a *PIK3CA* inhibitor. KIM-161 has significant antiproliferative activity with IC₅₀ values of 1.428 and 1.562 µM against PI3KCA mutant breast cancer MCF7 and T47D cells, respectively. KIM-161 induces apoptosis and cell cycle arrest by inhibiting the *PI3K/AKT/mTOR* signaling pathway and inducing ROS production. KIM-161 can be used to study breast cancer and its PI3KCA mutant subtypes .

HY-138302

PF-06862309	Drug Intermediate	Cancer
PF-06862309 is a PF-06843195 (HY-131972) phosphate ester prodrug. PF-06862309 can be hydrolyzed to PF-06843195 in the presence of alkaline phosphatase. PF-06843195 is a highly selective PI3Kα inhibitor. PF-06862309 can be used for the study of breast cancer with ER ⁺, HER ^2-, and PIK3CA mutations .

HY-116191

WJD008	PI3K mTOR	Cancer
WJD008 is a potent dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor with antiproliferative and anticlonogenic activity in tumor cells and transformed cells with PIK3CA mutant. WJD008 inhibits kinase activity of PI3K α and mTOR and abrogates insulin-like growth factor-I-activated PI3K-Akt-mTOR signaling cascade. WJD008 is promising for research of cancers .

HY-100886R

BAY1082439 (Standard)	PI3K Reference Standards Apoptosis	Cancer
BAY1082439 (Standard) is the analytical standard of BAY1082439 (HY-100886). This product is intended for research and analytical applications. BAY1082439 is an orally bioavailable, selective PI3Kα/β/δ inhibitor. BAY1082439 also inhibits mutated forms of PIK3CA. BAY1082439 is highly effective in inhibiting Pten-null prostate cancer growth .

HY-108232R

MK-2206 (Standard)	Organoid Reference Standards Akt Autophagy Apoptosis	Cancer
MK-2206 (Standard) is the analytical standard of MK-2206 (HY-108232). This product is intended for research and analytical applications. MK-2206 is an orally active, highly potent and selective allosteric Akt inhibitor, with IC₅₀s of 8, 12, and 65 nM for Akt1, Akt2, and Akt3, respectively. Many breast cancer cell lines, and PIK3CA-mutant and cell lines with PTEN loss are sensitive to MK-2206. MK-2206 has anticancer activities .

HY-100424

PI3K-IN-63	PI3K Akt	Cancer
PI3K-IN-63 is a selective PI3Kα inhibitor with a K_i of 0.35 nM against human targets. PI3K-IN-63 inhibits the phosphorylation of AKT at the S473 site in cellular assays. PI3K-IN-63 reduces the viability of non-small cell lung cancer cell lines carrying PIK3CA mutations. PI3K-IN-63 can be used in studies related to non-small cell lung cancer .

HY-10358R

MK-2206 dihydrochloride (Standard) MK-2206 (2HCl) (Standard)	Organoid Reference Standards Akt Autophagy Apoptosis	Cardiovascular Disease Inflammation/Immunology Cancer
MK-2206 dihydrochloride (MK-2206 2HCl) (Standard) is the analytical standard of MK-2206 dihydrochloride (HY-10358). This product is intended for research and analytical applications. MK-2206 dihydrochloride is an orally active pan-AKT inhibitor, with IC₅₀ values of 8 nM, 12 nM and 65 nM against AKT1, AKT2 and *AKT3, respectively. MK-2206 dihydrochloride inhibits the Akt/mTOR* signaling pathway and reduces the levels of downstream *GSK3β* and Mcl-1 via proteasomal degradation. MK-2206 dihydrochloride induces G1-phase cell cycle arrest, apoptosis, epithelial-mesenchymal transition, fibroblast activation and extracellular matrix deposition. MK-2206 dihydrochloride causes transient hyperglycemia and hyperinsulinemia in animals. MK-2206 dihydrochloride can be used in research related to solid tumors, renal fibrosis and hypercholesterolemia ^[3] .

HY-183770

LCI40	Akt PI3K Epigenetic Reader Domain c-Myc	Cancer
LCI40 is an orally active dual *PI3K/BRD4* inhibitor (PI3Kα IC₅₀ = 0.071 μM, PI3Kβ IC_{50 =}0.17 μM, PI3Kγ IC₅₀ = 0.66 μM, PI3Kδ IC₅₀ = 0.072 μM, BRD4 BD1 IC₅₀ = 0.19 μM, and BRD4 BD2 IC₅₀ = 1.88 μM. LCI40 inhibits phosphorylation of pAKT (S473) and suppresses c-MYC levels in mantle cell lymphoma cells. LCI40 displays immunomodulatory capacity with minimal toxicity to normal mouse immune cells. LCI40 can be used for the research of mantle cell lymphoma .

HY-183285

PI3Kα-IN-32	PI3K Akt	Cancer
PI3Kα-IN-32 (Compound 11f) is a selective, orally active PI3Kα inhibitor, with an IC₅₀ of 26.3 nM against PI3Kα ^H1047R. PI3Kα-IN-32 inhibits AKT phosphorylation. PI3Kα-IN-32 exhibits anticancer activity against breast cancer. PI3Kα-IN-32 can be used in the research of HR ⁺/HER2 ^- breast cancer .

Cat. No.	Product Name

HY-L015

PI3K/Akt/mTOR Compound Library	1,049 compounds
The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials. MCE owns a unique collection of 1,049 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

PI3K/Akt/mTOR Compound Library

1,049 compounds

The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.

MCE owns a unique collection of 1,049 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N12726

Halociline	Microorganisms Marine natural products Phenols Marine microorganism Source Classification	p38 MAPK MMP
Halociline, a derivative of alkaloids, that can be isolated from the marine fungus Penicillium griseofulvum. Halociline targets MAPK1, MMP-9, and PIK3CA in gastric cancer cells, potentially mediated by diverse pathways including cancer, lipid metabolism, atherosclerosis, and EGFR tyrosine kinase inhibitor resistance. Halociline possesses antimicrobial, antioxidant and biofilm inhibitory activities .

Recombinant Proteins Recommended:

PIK3CA

Species:	Human (9)
Tag:	His (2) Tag Free (1) Strep (2) Avi (6)
Source:	Sf9 insect cells (9)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P705719

	PIK3CA Protein, Human (sf9, His, StrepⅡ) Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha; PtdIns-3-kinase subunit p110-alpha; p110alpha; Phosphoinositide 3-kinase alpha; Phosphoinositide-3-kinase catalytic alpha polypeptide; Serine/threonine protein kinase pik3ca; 2.7.11.1; pik3ca; Homo sapiens; Human; PI3-kinase subunit alpha; Kinase; Serine/threonine-protein kinase; Transferase; 2.7.1.137	Human	Sf9 insect cells
	PIK3CA Protein, Human (sf9, His, StrepⅡ) is the recombinant human-derived PIK3CA, expressed by sf9 insect cells , with Strep, His labeled tag.

HY-P703580

	PIK3CA Protein, Human (Active, H1047R, sf9, His, StrepⅡ) 1 Publications Verification Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha; PtdIns-3-kinase subunit p110-alpha; p110alpha; Phosphoinositide 3-kinase alpha; Phosphoinositide-3-kinase catalytic alpha polypeptide; Serine/threonine protein kinase pik3ca; 2.7.11.1; pik3ca; Homo sapiens; Human; PI3-kinase subunit alpha; Kinase; Serine/threonine-protein kinase; Transferase; 2.7.1.137	Human	Sf9 insect cells
	PIK3CA Protein, Human (Active, H1047R, sf9, His, StrepⅡ) is the recombinant human-derived PIK3CA, expressed by sf9 insect cells , with Strep, His labeled tag.

HY-P703583

	p85α/p110α Protein, Human (Active, sf9) pik3R1&pik3ca	Human	Sf9 insect cells

HY-P703467

	p85α/p110α Protein, Human (Active, Biotinylated, sf9, Avi) pik3R1&pik3ca	Human	Sf9 insect cells

HY-P703466

	p85α/p110α Protein, Human (Active, H1047R, Biotinylated, sf9, Avi) pik3R1&pik3ca	Human	Sf9 insect cells

HY-P703468

	p85α/p110α Protein, Human (Active, E542K, Biotinylated, sf9, Avi) pik3R1&pik3ca	Human	Sf9 insect cells
	p85/p110 Protein, Human (Active, E542K, Biotinylated, sf9, Avi) is the recombinant human-derived p85/p110, expressed by sf9 insect cells , with Avi labeled tag. ,

HY-P703469

	p85α/p110α Protein, Human (Active, E545K, Biotinylated, sf9, Avi) pik3R1&pik3ca	Human	Sf9 insect cells
	p85/p110 Protein, Human (Active, E545K, Biotinylated, sf9, Avi) is the recombinant human-derived p85/p110, expressed by sf9 insect cells , with Avi labeled tag. ,

HY-P703470

	p85α/p110α Protein, Human (Active, N345K, Biotinylated, sf9, Avi) pik3R1&pik3ca	Human	Sf9 insect cells
	p85/p110 Protein, Human (Active, N345K, Biotinylated, sf9, Avi) is the recombinant human-derived p85/p110, expressed by sf9 insect cells , with Avi labeled tag. ,

HY-P703471

	p85α/p110α Protein, Human (Active, P539R, Biotinylated, sf9, Avi) pik3R1&pik3ca	Human	Sf9 insect cells
	p85/p110 Protein, Human (Active, P539R, Biotinylated, sf9, Avi) is the recombinant human-derived p85/p110, expressed by sf9 insect cells , with Avi labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Rabbit (3)
Reactivity:	Human (3) Rat (3) Mouse (3)
Application:	ICC/IF (3) IP (3) WB (3) ELISA (1)
Isotype:	IgG (3)
Conjugation:	Non-conjugated (3) Biotin (6)
Clonality:	Monoclonal (3) Recombinant (2)
Modification:	Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86078

	*PI3 Kinase p110 alpha/PIK3CA* Antibody (YA5770)** 5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha; 5-bisphosphate 3-kinase catalytic subunit alpha isoform; caPI3K; CLOVE; CWS5; MCAP; MCM; MCMTC; MGC142161; MGC142163; p110 alpha; p110alpha; Phosphatidylinositol 3 kinase catalytic alpha polypeptide; Phosphatidylinositol 3 kinase catalytic 110 KD alpha; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha isoform; Phosphatidylinositol 4,5 bisphosphate 3 kinase 110 kDa catalytic subunit alpha; Phosphatidylinositol-4; Phosphoinositide 3 kinase catalytic alpha polypeptide; PI 3 Kinase catalytic subunit alpha; PI3 kinase p110 subunit alpha; PI3-kinase subunit alpha; PI3K; PI3K-alpha; PI3KC A; pik3C A; pik3ca; PK3ca; PK3ca_HUMAN; PtdIns 3 kinase p110; PtdIns-3-kinase subunit alpha; PtdIns-3-kinase subunit p110-alpha; Serine/threonine protein kinase pik3ca	WB, ICC/IF, IP, ELISA	Human, Mouse, Rat
	PI3 Kinase p110 alpha/PIK3CA Antibody (YA5770) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PI3 Kinase p110 alpha/PIK3CA.

HY-P81162A

	*PI3 Kinase p110 alpha/PIK3CA* Antibody (PBS only)** PI3 kinase p110 subunit alpha; caPI3K; MGC142161; MGC142163; p110 alpha; Phosphatidylinositol 3 kinase catalytic alpha polypeptide; Phosphatidylinositol 3 kinase catalytic 110 KD alpha; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha isoform; Phosphoinositide 3 kinase catalytic alpha polypeptide; PI3 kinase p110 subunit alpha; PI3K; PI3KC A; pik3C A; PK3ca; PtdIns 3 kinase p110; PI3-kinase P110α; PI3-kinase p110 subunit alpha; PI 3 Kinase catalytic subunit alpha; PK3ca_HUMAN; PI3 kinase P110α.	WB, ICC/IF, IP	Human, Mouse, Rat
	PI3 Kinase p110 alpha/PIK3CA Antibody (PBS only) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PI3 Kinase p110 alpha/PIK3CA.

HY-P81162

	*PI3 Kinase p110 alpha/PIK3CA* Antibody (YA3537)** PI3 kinase p110 subunit alpha; caPI3K; MGC142161; MGC142163; p110 alpha; Phosphatidylinositol 3 kinase catalytic alpha polypeptide; Phosphatidylinositol 3 kinase catalytic 110 KD alpha; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha isoform; Phosphoinositide 3 kinase catalytic alpha polypeptide; PI3 kinase p110 subunit alpha; PI3K; PI3KC A; pik3C A; PK3ca; PtdIns 3 kinase p110; PI3-kinase P110α; PI3-kinase p110 subunit alpha; PI 3 Kinase catalytic subunit alpha; PK3ca_HUMAN; PI3 kinase P110α.	WB, ICC/IF, IP	Human, Mouse, Rat
	PI3 Kinase p110 alpha/PIK3CA Antibody (YA3537) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PI3 Kinase p110 alpha/PIK3CA.